Therefore, the results of our current study might shed further light on the molecular subclassifications of BRCA-related breast cancers and ultimately lead to a better characterization of the molecular tumor type that would benefit from PARP inhibitors. This evidence concerns the gene PARP1 and breast carcinoma.